Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL
Researchers sought to determine whether combination pola-R-CHP would be cost-effective for patients with previously untreated DLBCL.
Researchers sought to determine whether combination pola-R-CHP would be cost-effective for patients with previously untreated DLBCL.
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
A large proportion of patients with relapsed/refractory diffuse large B-cell lymphoma do not undergo repeat biopsy, a study suggests.
A model including 4 clinical factors can predict overall survival, with predictive performance superior to the Ann Arbor staging system.
Researchers sought to develop a model to classify patients with diffuse large B-cell lymphoma into prognostic subgroups.
This phase 3 trial is designed to compare loncastuximab tesirine plus rituximab with standard immunochemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.